NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS
- Active, not recruiting
- Dec 12, 2014
- 1 min read
Updated: May 23, 2022
CENTAURUS
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02316106
Official Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
First Posted : December 12, 2014
Click here to see details on ClinicalTrials.gov
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
Adv Ther. 2021 Feb
Click here to see details
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Leukemia. 2020 Jul
Click here to see details
Locations
United States, Arkansas
United States, Florida
United States, Georgia
United States, Massachusetts
United States, Michigan
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, Tennessee
United States, Washington
Canada, Alberta
Canada, Ontario
Europe
United Kingdom
Czechia
France
Germany
Netherlands
Russian Federation
Asia
Turkey
Israel
Australia